Search research articles
Contact Us
Filters
Showing results (61-70 of 179) with videos related to
Page
of 18
Sort By:
Lancet (London, England)
|
March 27, 2007
Development of a rational scale to assess the harm of drugs of potential misuse
David Nutt, Leslie A King, William Saulsbury, et al.
BMJ (Clinical Research Ed.)
|
October 16, 2024
Should recreational cannabis be legalised in the UK?
David Nutt, Lucy Stafford, Robin M Murray, et al.
The European Journal of Neuroscience
|
June 7, 2016
Introduction to the 2016 Consensus Document on European Brain Research
Monica Di Luca, Paul Bolam, John Foxe, et al.
Journal of Psychopharmacology (Oxford, England)
|
January 25, 2013
Generic legislation of new psychoactive drugs
Jan van Amsterdam, David Nutt, Wim van den Brink
Naunyn-Schmiedeberg'S Archives of Pharmacology
|
September 22, 2016
Neurochemical binding profiles of novel indole and benzofuran MDMA analogues
Jakob A Shimshoni, Ilan Winkler, Ezekiel Golan, et al.
Scientific Reports
|
July 26, 2023
The difference between 'placebo group' and 'placebo control': a case study in psychedelic microdosing
Balázs Szigeti, David Nutt, Robin Carhart-Harris, et al.
The Journal of Clinical Psychiatry
|
March 28, 2008
Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression
Madhukar H Trivedi, Eric Hollander, David Nutt, et al.
Psychopharmacology
|
January 22, 2003
Effects on sleep architecture of pindolol, paroxetine and their combination in healthy volunteers
Caroline Bell, Sue Wilson, Ann Rich, et al.
Human Psychopharmacology
|
October 31, 2002
GABAAbenzodiazepine receptor (GBzR) sensitivity: test-retest reliability in normal volunteers
John Potokar, John Nash, John Sandford, et al.
BMJ Open
|
September 22, 2020
So near yet so far: why won't the UK prescribe medical cannabis?
David Nutt, Steve Bazire, Lawrence D Phillips, et al.
Page
of 18
Search research articles
Search
Showing results (61-70 of 179) with videos related to
Sort By:
Page
of 18
Lancet (London, England)
|
March 27, 2007
Development of a rational scale to assess the harm of drugs of potential misuse
David Nutt, Leslie A King, William Saulsbury, et al.
BMJ (Clinical Research Ed.)
|
October 16, 2024
Should recreational cannabis be legalised in the UK?
David Nutt, Lucy Stafford, Robin M Murray, et al.
The European Journal of Neuroscience
|
June 7, 2016
Introduction to the 2016 Consensus Document on European Brain Research
Monica Di Luca, Paul Bolam, John Foxe, et al.
Journal of Psychopharmacology (Oxford, England)
|
January 25, 2013
Generic legislation of new psychoactive drugs
Jan van Amsterdam, David Nutt, Wim van den Brink
Naunyn-Schmiedeberg'S Archives of Pharmacology
|
September 22, 2016
Neurochemical binding profiles of novel indole and benzofuran MDMA analogues
Jakob A Shimshoni, Ilan Winkler, Ezekiel Golan, et al.
Scientific Reports
|
July 26, 2023
The difference between 'placebo group' and 'placebo control': a case study in psychedelic microdosing
Balázs Szigeti, David Nutt, Robin Carhart-Harris, et al.
The Journal of Clinical Psychiatry
|
March 28, 2008
Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression
Madhukar H Trivedi, Eric Hollander, David Nutt, et al.
Psychopharmacology
|
January 22, 2003
Effects on sleep architecture of pindolol, paroxetine and their combination in healthy volunteers
Caroline Bell, Sue Wilson, Ann Rich, et al.
Human Psychopharmacology
|
October 31, 2002
GABAAbenzodiazepine receptor (GBzR) sensitivity: test-retest reliability in normal volunteers
John Potokar, John Nash, John Sandford, et al.
BMJ Open
|
September 22, 2020
So near yet so far: why won't the UK prescribe medical cannabis?
David Nutt, Steve Bazire, Lawrence D Phillips, et al.
Page
of 18